Pharma News
Insulin biosimilars: new CRL for Biocon, new deal for Meitheal/Tonghua Dongbao
In a dynamic landscape of pharmaceutical developments, Biocon Biologics (Biocon) faces a regulatory hurdle with a complete response letter from the US Food and Drug Administration (FDA), while Meitheal Pharmaceuticals expands its reach through a strategic licensing agreement with Tonghua Dongbao Pharmaceutical.
Abbott and mAbxience partnership for biosimilars in emerging markets
Abbott and mAbxience announced on 20 September 2023 that they had entered into a strategic partnership to commercialize several biosimilars in Latin America and other emerging markets.
Fresenius Kabi and Formycon reach agreement with J&J, Alvotech and Teva expand partnership
In August 2023, Fresenius Kabi and Formycon announced that they have entered into a settlement agreement with Johnson & Johnson (J&J) concerning FYB202, a proposed ustekinumab biosimilar in the US. This followed the late July 2023 news that Alvotech and Teva Pharmaceuticals (Teva) have agreed to expand their existing strategic partnership agreement.
Cuba and China strengthen ties in biotechnology
The biotechnological cooperation between Cuba and China has been a longstanding relationship in the scientific and technological realms. For the benefit of both countries, Havana and Beijing have undertaken various collaborations in the field of biotechnology, driven by their bilateral relations and shared interest in the development of the healthcare and pharmaceutical industry.
New BioFactura-CuraTeQ partnership for ustekinumab biosimilar
CuraTeQ Biologics Private Limited, a subsidiary of India’s Aurobindo Pharma Limited, has entered into an exclusive license agreement to commercialize BFI-751, BioFactura’s proposed biosimilar to Stelara (ustekinumab).
Four drugmakers sue the US government over the Inflation Reduction Act
In July 2023, Johnson & Johnson became the fourth large drugmaker to sue the US government over drug price negotiations in the Inflation Reduction Act (IRA). They join, Merck, Bristol Myers Squibb and Astellas in claiming that price negotiations by Medicare violate the First and Fifth Amendments of the US Constitution.
Celltrion–Rani partnership for RaniPill biosimilars
Celltrion and Rani Therapeutics (Rani) have entered a partnership under which Celltrion will supply ustekinumab and adalimumab biosimilars for RaniPill products under an exclusive license and supply agreement.
Cuba strengthens biotech industry through Eurasian partnerships
Cuba is consolidating its position in the field of biotechnology thanks to cooperation with several Eurasian nations, in particular Russia and Belarus.
Biosimilars manufacturing facilities approved by EU and US
Two biological drugs manufacturing facilities for biosimilar epoetin alfa and biosimilar bevacizumab were approved in the US and Europe in May and April 2023, respectively.
Cuba and China strengthen scientific cooperation for the development of medical treatments
In recent years, Cuba and China have established agreements to develop innovative medical treatments, notably Center for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología, CIGB) and Center for Molecular Immunology (Centro de Inmunología Molecular, CIM), and have shared their experiences in the field of medical research.
